硬膜外阻滞联合普瑞巴林治疗带状疱疹后神经痛的临床研究

Clinical use of epidural block combined with pregabalin in postherpetic neuralgia

目的:探讨硬膜外阻滞联合普瑞巴林治疗带状疱疹后神经痛(PHN)的疗效。方法:选取2018年12月至2019年10月本院收治的PHN患者60例,随机分为研究组与对照组,每组30例。对照组给予普瑞巴林治疗,研究组给予硬膜外阻滞联合普瑞巴林治疗。比较两组治疗前后疼痛视觉模拟评分(VAS),治疗后1、5、10 d普瑞巴林用量和匹兹堡睡眠质量指数量表(PSQI)等指标,记录治疗期间的不良反应。结果:治疗前、治疗后1 d,两组VAS评分差异均无统计学意义(均P>0.05)。治疗后2~10 d,研究组VAS评分均低于对照组(均P<0.05)。治疗后1 d,两组普瑞巴林用量、PSQI评分比较,差异无统计学意义(均P>0.05);治疗后5、10 d,研究组普瑞巴林用量及PSQI评分均低于对照组(均P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论:硬膜外阻滞联合普瑞巴林治疗PHN具有较好的临床疗效。

Objective:To investigate the efficacy of epidural block combined with pregabalin in postherpetic neuralgia(PHN).Methods:Sixty PHN patients treated in our hospital between December 2018 and October2019 were included as subjects and randomized into the study group and control group(n=30 each).The control group was treated with pregabalin alone and the study group with epidural block combined with pregabalin.The visual analogue score(VAS)of pain before and after treatment,pregabalin use and Pittsburgh Sleep Quality Index(PSQI)scale at 1,5 and 10 days of treatment,and adverse reactions during treatment were compared between the two groups.Results:There was no significant difference in VAS score between the two groups before and at 1 day of treatment(P>0.05).At days 2 through 10 of the treatment,the VAS score in the study group was significantly lower than that in the control group(P<0.05).At 1 day of treatment,there was no significant differences in pregabalin use and PSQI score between the two groups(P>0.05).At 5 and 10 days of treatment,the pregabalin dosage and PSQI score in the study group were significantly lower than those in the control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Epidural block combined with pregabalin offers good clinical efficacy in treatment of postherpetic neuralgia.